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91 Abstract This study aims to characterize myositis-specific antibodies in a
well-defined cohort of patients with idiopathic inflammatory
myopathy and to determine their association with cancer. Sera
from 40 patients with polymyositis, dermatomyositis, and controls
were tested by protein and RNA immunoprecipitation to detect
autoantibodies, and immunoprecipitation-Western blot was used for
anti-MJ/NXP-2, anti-MDA5, and anti-TIF1γ/α identification. Medical
records were re-evaluated with specific focus on cancer.
Anti-MJ/NXP-2 and anti-TIF1γ/α were the most common antibodies
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in dermatomyositis. In six dermatomyositis cases, we found five
solid forms of cancer and one Hodgkin’s lymphoma in long-term
remission. Among patients with cancer-associated dermatomyositis,
three were positive for anti-TIF1γ/α, two for anti-Mi-2, and one for
anti-MJ/NXP-2. The strongest positivity of anti-TIF1γ was seen in
two active forms of cancer, and this antibody was either negative or
positive at low titers in the absence of cancer or in the 7-year
remission Hodgkin’s lymphoma. Four out of twenty (20 %) patients
with polymyositis had solid cancer, but no specific association with
autoantibodies was identified; further, none of the four cases of
antisynthetase syndrome had a history of cancer. No serum
myositis-associated autoantibody was observed in control sera,
resulting in positive predictive value 75 %, negative predictive
value 78.5 %, sensitivity 50 %, specificity 92 %, and area under the
ROC curve 0.7083 for the risk of paraneoplastic DM in anti-TIF1γ/α
(+) patients. Myositis-specific autoantibodies can be identified
thanks to the use of immunoprecipitation, and their association with
cancer is particularly clear for anti-TIF1γ/α in dermatomyositis. This
association should be evaluated in a prospective study by
immunoprecipitation in clinical practice.
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13 AbstractQ2 This study aims to characterize myositis-specific
14 antibodies in a well-defined cohort of patients with idiopathic
15 inflammatory myopathy and to determine their association
16 with cancer. Sera from 40 patients with polymyositis, derma-
17 tomyositis, and controls were tested by protein and RNA im-
18 munoprecipi ta t ion to detect autoant ibodies , and
19 immunoprecipitation-Western blot was used for anti-MJ/
20 NXP-2, anti-MDA5, and anti-TIF1γ/α identification.
21 Medical records were re-evaluated with specific focus on can-
22 cer. Anti-MJ/NXP-2 and anti-TIF1γ/α were the most com-
23 mon antibodies in dermatomyositis. In six dermatomyositis
24 cases, we found five solid forms of cancer and one
25 Hodgkin’s lymphoma in long-term remission. Among patients
26 with cancer-associated dermatomyositis, three were positive
27 for anti-TIF1γ/α, two for anti-Mi-2, and one for anti-MJ/
28 NXP-2. The strongest positivity of anti-TIF1γ was seen in
29 two active forms of cancer, and this antibody was either neg-
30 ative or positive at low titers in the absence of cancer or in the
31 7-year remission Hodgkin’s lymphoma. Four out of twenty
32 (20 %) patients with polymyositis had solid cancer, but no
33 specific association with autoantibodies was identified;
34further, none of the four cases of antisynthetase syndrome
35had a history of cancer. No serum myositis-associated autoan-
36tibody was observed in control sera, resulting in positive pre-
37dictive value 75 %, negative predictive value 78.5 %, sensi-
38tivity 50 %, specificity 92 %, and area under the ROC curve
390.7083 for the risk of paraneoplastic DM in anti-TIF1γ/α (+)
40patients. Myositis-specific autoantibodies can be identified
41thanks to the use of immunoprecipitation, and their associa-
42tion with cancer is particularly clear for anti-TIF1γ/α in der-
43matomyositis. This association should be evaluated in a pro-
44spective study by immunoprecipitation in clinical practice.
45Keywords Biomarkers . Cancer . Idiopathic inflammatory
46myositis . Immunoprecipitation
47Introduction
48Idiopathic inflammatory myopathy (IIM) is characterized by
49muscle inflammation, skin alterations, and internal organ in-
50volvement, resulting inmuscle atrophy, skinmicroangiopathy,
51and tissue fibrosis [1]. IIMs are divided into several conditions
52with polymyositis (PM) and dermatomyositis (DM) as the
53most frequent forms despite being considered rare worldwide
54[2]. Beyond the clinical and histopathological differences, PM
55and DM can be further classified into subsets thanks to
56myositis-specific autoantibodies (MSA) which have diagnos-
57tic and prognostic roles [3, 4]. Some MSA have been known
58for decades, as for the anti-Jo-1 characterizing the
59antisynthetase syndrome or anti-Mi-2, peculiar for DM [5,
606]. Several MSA have been defined most recently by protein
61and RNA immunoprecipitation (IP). Paradigmatic MSA in-
62clude DM-associated anti-MDA5, anti-MJ/NXP-2, and anti-
63TIF1γ/αwhich define specific clinical features and predict the
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64 association with cancer [2, 6, 7], sometimes without indepen-
65 dent confirmation [8].
66 To validate the proposed clinical associations, we utilized
67 IP for MSA in a well-characterized cohort of patients with PM
68 and DM from two clinical centers, with particular focus on the
69 specificities identified in recent years and their association
70 with cancer.
71 Materials and methods
72 Patients
73 The study included IIMs patients followed at the outpatient
74 clinic at Humanitas Research Hospital (Rozzano, Milan, Italy)
75 and Spedali Civili (Brescia, Italy) in the period 2013–2016.
76 We included sera from 20 patients with PM, 2 with
77 antisynthetase syndrome, 18 with DM, and controls represent-
78 ed by healthy subjects (NHS; n = 12) and patients with sys-
79 temic sclerosis (SSc; n = 79), Behçet’s disease (BD; n = 45),
80 and psoriatic arthritis (PsA; n = 145). We used established
81 criteria for the diagnosis of PM/DM, SSc, BD, and PsA and
82 collected clinical and laboratory data at enrollment.
83 The study was approved by the Institutional Review Board
84 of the hospitals and informed consent was obtained from all
85 subjects.
86 Methods for autoantibody analysis
87 Patients’ sera were isolated from whole blood through centri-
88 fugation at 2000g for 15 min, and then stored in −20 °C freez-
89 er until use. MSAwere first screened by protein-IP using 35S-
90 methionine-labeled K562 cell extract followed by SDS-PAGE
91 and autoradiography, and by RNA-IP using unlabeled K562
92 cell extract followed by urea-PAGE and silver staining [9, 10].
93 MSAwere determined using reference sera obtained from the
94 Autoantibody Standardization Committee (www.autoab.org)
95 and from internal controls.
96 Candidates for anti-MJ/NXP-2 and anti-MDA5 were
97 tested by IP-Western Blot (IP-WB) based on IP of a
98 140-kD protein, while candidates for anti-TIF1γ/α were
99 selected based on bands at 155–140 kD by protein-IP. In
100 detail, 8 μl of candidate sera were cross-linked with
101 protein-A Sepharose beads and then immunoprecipitated
102 with cell extract from 107 K562 cells. Proteins were then
103 fractionated by 8 % SDS-PAGE and transferred to a ni-
104 trocellulose filter, probed with 1 μg/ml of anti-MORC3
105 mouse polyclonal antibody (Abnova, Taipey City,
106 Taiwan) for MJ/NXP-2, followed by horseradish peroxi-
107 dase (HRP) goat anti-mouse IgG (1:5000 dilution)
108 (ThermoFisher, Waltham, MA, USA) and developed
109 using Immobilon Western Chemiluminescent HRP sub-
110 strate (Millipore, Darmstadt, Germany). The same
111procedure was used for anti-MDA5 antibodies using
1121:1000 rabbi t ant i -MDA5 ant ibody (Mil l ipore ,
113Darmstadt, Germany) followed by 1:5000 HRP-
114conjugated goat anti-rabbit Ig light chain antibody
115(Jackson Immunoresearch, West Grove, PA, USA), and
116developed using Supersignal West Femto (ThermoFisher,
117Waltham, MA, USA). For TIF1γ IP-WB, we used 1:1000
118mouse monoclonal anti-TIF1γ antibody (Abcam,
119Cambridge, UK), followed by 1:10.000 HRP goat anti-
120mouse IgG (ThermoFisher, Waltham, MA, USA), and de-
121veloped using Immobilon Western Chemiluminescent
122HRP substrate (Millipore, Darmstadt, Germany).
123Statistical analysis
124All comparisons were performed by Mann-Whitney test and
125Pearson Chi square test using Stata 13.1 for Macintosh
126(StataCorp, 2013, CollegeStation, Texas, USA) and Prism
127version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).
128Statistical significance was accepted as p < 0.05.
129Results
130Through protein- and RNA-IP, we identified serum auto-
131antibodies in IIMs as illustrated in Fig. 1a. None of our
132control sera were positive for MSA. Before using IP and
133IP-WB, only 6/18 (33 %) DM and 4/20 (20 %) PM cases
134had autoantibodies detected by routine autoimmunity
135tests, particularly anti-Ro/SSA, La/SSB, Mi-2, and -Jo-1.
136Thanks to IP analysis, we confirmed this positivity and
137identified additional MSA in patients with positive anti-
138nuclear antibodies (ANA) by indirect immunofluores-
139cence but negative autoantibody for extractable nuclear
140antigens (ENA). We did not observe double autoantibody
141positivity in our cohort, except for the association of Ro/
142SSA, La/SSB, and Jo-1 as reported [11]. Protein- and
143RNA-IP confirmed two less common antisynthetase anti-
144bodies as anti-EJ (anti-glycyl tRNA synthetase) and anti-
145PL-12 (anti-alanyl tRNA synthetase) in one PM and one
146antisynthetase syndrome case, respectively (Fig. 1a).
147Using RNA-IP, we identified the 7SL RNA band charac-
148teristic of anti-SRP antibodies, in association with anti-
149Ro/SSA in one patient with PM (Fig. 1b), and in both
150cases necrotizing myositis was seen at muscle biopsy.
151Eight cases (1 DM and 7 PM) remain seronegative by
152IP, while in six DM cases, we identified bands at different
153molecular weight by protein-IP but their antigenic signif-
154icance is still unknown (data not shown). Nine samples (5
155IIMs and 4 SSc) had one band detectable around 140 kD
156by protein IP, and were tested by IP-WB for anti-MJ/
157NXP-2 and -MDA5 antibodies to identify the specificity
158corresponding to this band. In three DM cases, we
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159 confirmed the anti-MJ/NXP-2 positivity (Fig. 1c, d),
160 while no MSA was detected in our control population.
161 The main clinical and laboratory features of patients are
162 described in Table 1. The diagnosis of myositis was confirmed
163 by muscle biopsy and/or electromyography only in 13/18
164 (72 %) of DM patients, coined clinically amyopathic DM.
165 No significant difference was detected for organ involvement,
166 laboratory tests abnormalities, and ongoing therapies in DM
167 and PM patients, while the expression of anti-TIF1γ/α
168antibodies was significantly associated to DM patients
169(p = 0.04) as shown in Table 1. The ANA pattern reported
170by routine autoimmunity tests was very variable for titer and
171pattern, and in some cases also defined as “negative” (Tables 1
172and 2), thus it was necessary to proceed with further testing by
173IP for the identification of MSA. Two anti-MJ/NXP-2 neces-
174sary to proceed with further testing by IP for the identification
175of MSA. Two anti-MJ/NXP-2 (+) DM patients had severe
176diffuse calcinosis that required surgical removal in one case,
Fig.Q3 1 MSA identified in our cohort of Italian PM/DM through the use of
protein-IP, RNA-IP, and IP-WB. a Bar graph showing the specific
autoantibodies and the number of corresponding cases identified in our
cohort of PM/DM patients. b RNA-IP of two positive SRP samples,
recognized by the band corresponding to 7SL RNA (black arrow). In
one case, association with anti-Ro/SSA antibodies was identified (black
vertical line) and supported by protein-IP (data not shown). The three
negative RNA-IP samples shown are the anti-MJ/NXP-2 (+) patients
reported in c and d, that typically do not show reactivity by RNA-IP.
Total RNA was used as positive control. c Protein-IP (8 % SDS-PAGE
gel) of representative PM/DM patients and corresponding autoantibodies:
two anti-TIF1γ/α (+) cases shown by the bands at 155/140 kD (black
arrows; two additional cases not shown in this protein-IP gel were
identified based on the mobility of the same bands), two anti-Mi-2 (+)
cases shown by the 240, 150, 72, 65, 63, 50, and 34 kD bands (black
arrow for the 240 kD band), and the three anti-MJ/NXP-2 (+) cases
identified by the 140 kD band (black arrow). Five DM cases negative
for MSA are also shown, and one NHS (normal human serum) is present
in the last lane. d IP-WB for anti-MJ/NXP-2 positive cases. The three
anti-MJ/NXP-2 (+) cases shown in the protein-IP gel in c were tested
together with other samples (myositis and SSc) that had 140 kD band at
protein-IP; no SSc sample had positivity for MJ/NXP-2. This panel also
represents in which cases an association with cancer was present, as
described in Table 2. e IP-WB for anti-TIF1γ positive cases. The four
anti-TIF1γ (+) cases identified by protein-IP through the detection of the
155/140 kD bands were positive by IP-WB as shown in this panel. The
weakest sample (#1) was the only one not associated with cancer until the
moment of evaluation of the patient, sample #2 had a diagnosis of
Hodgkin’s Lymphoma 7 years before DM onset and it is now
considered in remission, sample#3 has active lung cancer, and
sample#4 has advanced ovary cancer. One normal human serum (NHS)
is represented in the last lane
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177 and ongoing therapy with pamidronate infusions in one case
178 of clinically amyopathic DM [12]. The association with can-
179 cer was present only in one DM case positive for this autoan-
180 tibody (Fig. 1d). No serum was positive for anti-MDA5 anti-
181 bodies, and in fact, no patient in our PM/DM cohort had
182 symptoms such as rapidly progressive interstitial lung disease
183 that are usually associated with this autoantibody [6]. The four
184 anti-TIF1γ (+) sera have history of cancer in the three stron-
185 gest positive cases (Fig. 1e), while the weakest positive case is
186 the only one without cancer history until the moment of our
187 clinical evaluation.
188 Cumulatively, we calculated the positive predictive value
189 (75 %), negative predictive value (78.5 %), sensitivity (50 %),
190 specificity (91.6 %), and area under the ROC curve (0.7083)
191 for the risk of paraneoplastic DM in anti-TIF1γ/α (+) patients
192 and these were compared to previous reports.
193Discussion
194The routine use of protein- and RNA-IP may increase the
195detection rate of rare autoantibodies in clinical practice, par-
196ticularly in rare conditions such as PM and DM, thus maxi-
197mizing the diagnostic and prognostic power of these bio-
198markers. In fact and despite the low incidence and prevalence
199worldwide, IIMs are characterized by wide clinical phenotype
200variability, mirrored by a significant number ofMSA.We thus
201utilized the sensitive and specific IP to identify autoantibody
202prevalence and clinical significance in a well-defined cohort
203of Italian patients affected by PM/DM, with particular focus
204on cancer associations.
205Our most relevant findings include that anti-MJ/NXP-2
206and -TIF1γ/α antibodies are the two most frequent MSA in
207DM cases previously anti-ENA negative at routine tests.
t1:1 Table 1 Main demographic and
clinical features of our cohort of
DM and PM patients, for which
we performed serum IP analysis.
Two anti-synthetase cases are not
included
t1:2 DM
(n = 18)
PM
(n = 20)
p
t1:3 Demographic features
t1:4 Female:Male 13:5 14:6 –
t1:5 Mean age at enrollment, years (range) 49
(21–75)
59
(29–83)
0.05
t1:6 Mean age at myositis onset, years (range) 42.5
(15–71)
53.5
(24–78)
ns
t1:7 Clinical features
t1:8 Myositis (%)* 13 (72) 20 (100) 0.01
t1:9 Raynaud’s phenomenon (%) 7 (39) 4 (20) ns
t1:10 Arthritis (%) 5 (28) 5 (25) ns
t1:11 Interstitial lung disease (%) 2 (11) 5 (25) ns
t1:12 Dysphagia (%) 2 (11) 7 (35) ns
t1:13 Cancer (%) 6 (33) 4 (20) ns
t1:14 Use of steroid therapy (%) 17 (94) 19 (95) ns
t1:15 Use of immunosuppressants (%) 16 (89) 16 (80) ns
t1:16 Laboratory features
t1:17 Median CK at myositis onset, U/l (25th–75th percentile) 1605
(92–5160)
1400
(842–3295)
ns
t1:18 ANA positive titer ≥1:320 (%) 9 (50) 11 (55) ns
t1:19 ENA identified by IP
t1:20 Anti-TIF1γ/α 4 (22) 0 0.04
t1:21 Anti-MJ/NXP-2 3 (17) 0 ns
t1:22 Anti-Mi-2 2 (11) 0 ns
t1:23 Anti-SRP 1+Ro/SSA(5) 1 (5) ns
t1:24 Anti-Jo-1 0 4+Ro/SSA (20) ns
t1:25 Anti-EJ 0 1 (5) ns
t1:26 Anti-PL-12 0 1 (5) ns
t1:27 Anti-HMGCR 0 0 –
t1:28 Anti-MDA5 0 0 –
ANA anti-nuclear antibodies, CK creatine kinase, ENA extractable nuclear antigen, GI gastro-intestinal, IP im-
munoprecipitation, ns not significant
*Confirmed by electromyography and/or muscle biopsy
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208 Accordingly, to what reported in the literature, our three anti-
209 MJ/NXP-2 (+) DM cases have juvenile onset DMwith typical
210 skin DM features, no internal organ involvement, and the
211 worst clinical manifestation is severe calcinosis [13]. All these
212 cases required immunosuppressive therapy beyond steroids to
213 control muscle inflammation, but in one case, DM was not
214 completely controlled and this unresponsive patient had a di-
215 agnosis of papillary thyroid cancer 12 years after the onset of
216 DM. In fact, cancer has been reported in adult anti-MJ/NXP-
217 2(+) DM patients despite not being confirmed in our previous
218 publication on a different Italian cohort [10, 14]. The identifi-
219 cation of anti-MJ/NXP-2 antibodies was based on the first
220 observation of a common band of 140 kD molecular weight
221by protein-IP, but it was then necessary to perform IP-WB to
222have a positive result for MJ/NXP-2. Anti-MDA5 antibodies
223also migrate in the same molecular weight range, but no sam-
224ple tested positive by IP-WB and it was concordant with the
225clinical observation that these samples did not show the sug-
226gestive clinical features (i.e., rapidly progressive interstitial
227lung disease) that are commonly referred to anti-MDA5
228positivity.
229We detected serum anti-TIF1γ/α antibodies in four DM
230cases, only in one case there was no history of cancer despite
231extensive screening exams and it was the weakest positive
232case. All the other three cases have cancer history. In one case,
233this autoantibody was present in a DM patient with Hodgkin’s
t2:1 Table 2 Main characteristics of the anti-MJ/NXP-2 (+) and TIF1γ/α (+) cases identified in our cohort of PM/DM patients. The cases described in this
table are shown in Fig. 1d, e
t2:2 Anti-MJ/NXP-2
case 1
Anti-MJ/NXP-2
case 2
Anti-MJ/NXP-2
case 3
Anti-TIF1γ/α
case 1
Anti-TIF1γ/α
case 2
Anti-TIF1γ/α
case 3
Anti-TIF1γ/α
case 4
t2:3 Demographic data
t2:4 Sex Female Female Male Male Female Female Female
t2:5 Age (years) 33 21 21 72 40 59 54
t2:6 Diagnosis DM CADM DM DM DM CADM DM
t2:7 Age at onset (years) 19 15 18 67 22 58 52
t2:8 Clinical data
t2:9 Skin lesions +
(Gottron’s
papules,
erythematosus
rash)
+
(Gottron’s
papules,
erythematosus
rash)
+
(V-neck
erythema)
+
(Gottron’s
papules,
erythematosus
rash)
+
(Gottron’s
papules,
heliotrope
rash)
+
(Gottron’s
papules,
erythematosus
rash)
+
(Gottron’s
papules,
erythematous
rash)
t2:10 Calcinosis +++ +++ − − − − −
t2:11 Myositis + − + + + − +
t2:12 Arthritis − − − − − − −
t2:13 Raynaud’s
phenomenon
− − − − − − +
t2:14 Interstitial lung
disease
− − − − − − −
t2:15 Cancer + − − – + + +
t2:16 Cancer location Thyroid − − − Hodgkin’s
lymphoma
Lung
adenocarcino-
ma
Ovary
t2:17 Age at cancer onset
(years)
31 − − − 15 56 52
t2:18 Immunosuppressive
therapy*
+
(PDN, HCQ,
MTX, CsA,
IV Ig, AZA)
+
(PLQ)
+
(PDN, PLQ,
MTX, IV Ig,
AZA, CsA)
+
(PDN, MMF)
+
(PDN, HCQ,
CTX, AZA)
− +
(PDN, MTX, IV
Ig)
t2:19 Laboratory data
t2:20 Increased CK at
myositis onset
+ − + + + − +
t2:21 CK at last visit + Normal Normal Normal Normal Normal +
t2:22 ANA 1:640
nuclear dots
1:160
speckled
1:80
speckled
Negative 1:160
speckled
Negative >1:640 speckled
ANA anti-nuclear antibodies, AZA azathioprine, CADM clinically amyopathic DM, CK creatine kinase, CsA cyclosporine, CTX cyclophosphamide,DM
dermatomyositis, HCQ hydroxychloroquine, IV Ig intravenous immunoglobulins, MMF mycophenolate mofetil, MTX methotrexate, PDN prednisone
*The order of these therapies corresponds to the chronological order they were used by the patients
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234 lymphoma diagnosed and treated 7 years prior to the onset of
235 DM features, and considered in remission at the time of the
236 blood draw. This is in contrast with previous reports of anti-
237 TIF1γ/α antibodies not found in juvenile DM cases associat-
238 ed with cancer and of the highest associated risk of malignan-
239 cy during the year prior to and the year after IIMs diagnosis
240 [15]. The two strongest samples positive for anti-TIF1γ/α
241 antibodies have active cancer unresponsive to treatment at
242 the time of blood drawn. It is also important to highlight the
243 fact that both our two anti-Mi-2(+) DM cases had a history of
244 breast cancer prior to DM onset but no higher risk of cancer
245 has been reported in association with this autoantibody [4].
246 Our estimate of the positive and negative predictive values,
247 sensitivity, specificity, and area under the ROC curve for the
248 risk of paraneoplastic DM in anti-TIF1γ/α (+) patients were
249 concordant to previous reports [16–21].
250 In our PM cohort, four cases of cancer were reported, in
251 three being diagnosed several years prior to and in one con-
252 comitant to the onset of PM; in all cases, solid forms affecting
253 the thyroid, colon, breast, skin, and only two of them had a
254 known autoantibody signature at routine tests represented by
255 anti-Ro/SSA antibodies. No tumor was reported in the four
256 cases affected by antisynthetase syndrome, and no MSAwas
257 identified in SSc, BD, PsA cases with or without a history of
258 cancer. No PM case showed positivity for anti-3-hydroxy-3-
259 methylglutaryl-coenzyme A reductase (HMGCR) antibodies
260 despite the onset of necrotizing myopathy after the use of
261 statin [3]. Other autoantibodies that were reported by routine
262 autoimmunity laboratories through techniques such as immu-
263 noblotting were not confirmed by IP, as for anti-PM/Scl
264 (PM100) and PL-7.
265 We collected data relative to indirect immunofluorescence
266 ANA patterns reported by routine laboratory tests, and we
267 observed that the most frequent ANA pattern reported in our
268 anti-MJ/NXP-2(+) and anti-TIF1γ/α(+) cases is speckled, and
269 in one anti-MJ/NXP-2(+) case, the presence of nuclear dots
270 suggestive for promyelocytic leukemia nuclear bodies was
271 reported, thus needing further evaluation [10]. Despite the
272 use of the most sensitive techniques, eight patients with
273 IIMs remained negative for both ANA and ENA, while in
274 six additional cases, we could identify bands by protein-IP,
275 but no clear specificity [22]. These gaps underline the existing
276 limitations in the identification of autoantibodies in rheumatic
277 diseases such as PM/DM which are mainly due to lack of
278 standardization for ANA and ENA, low number of positive
279 cases studied for autoantibodies clinical association, identifi-
280 cation of rare and new autoantibodies through time and labor-
281 consuming techniques such as IP, and the lack of commercial-
282 ly available techniques that may help in the identification of
283 rare autoantibodies in a clinical setting [23] and shed light on
284 PM/DM pathogenesis [2]. We acknowledge that the efforts of
285 international registries such as Euromyositis or the
286 Autoantibody Standardization Committee are expected to
287minimize the frequency of seronegative cases and to provide
288a clear estimate of the prevalence of rare autoantibodies [24].
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